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678Objective: There is limited information regarding the true incidence of and risk factors for chylothorax after
pediatric cardiac surgery. The objective of this study was to determine, from a large multi-institution database,
incidence, associated factors, and treatment strategy in patients undergoing pediatric cardiac surgery.
Methods: All patients younger than 18 years in the Pediatric Health Information System (PHIS) database who
underwent congenital heart surgery or heart transplant from 2004 to 2011 were included. Procedure complexity
was assessed by Risk Adjustment for Congenital Heart Surgery-1.
Results: In all, 77,777 patients (55% male) of median age 6.7 months were included. Overall incidence of
chylothorax was 2.8% (n ¼ 2205), significantly associated with increased procedure complexity, younger
age, genetic syndromes, vein thrombosis, and higher annual hospital volume. Patients with multiple congenital
procedures had the highest incidence. Incidence increased with time, from 2% in 2004 to 3.7% in 2011
(P<.0001). Chylothorax was associated with longer stay (P<.0001), increased adjusted risk for in-hospital
mortality (odds ratio, 2.13; 95% confidence interval, 1.75-2.61), and higher cost (P< .0001), regardless of
procedure complexity. Of all patients with chylothorax, 196 (8.9%) underwent thoracic duct ligation or
pleurodesis a median of 18 days after surgery. Total parenteral nutrition, medium-chain fatty acid supplemen-
tation, and octreotide were used in 56%, 1.7%, and 16% of patients, respectively.
Conclusions: Chylothorax is a significant problem in pediatric cardiac surgery and is associated with
increased mortality, cost, and length of stay. Strategies should be developed to improve prevention and
treatment. (J Thorac Cardiovasc Surg 2014;147:678–86)Supplemental material is available online.
The development of chylothorax after pediatric cardiac
surgery is a known complication associated with significant
respiratory, nutritional, immunologic, hematologic, and
metabolic morbidity.1 It has been associated with longer
ventilation dependence,2 longer postoperative stay,3 and
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The Journal of Thoracic and Cardiovascular Surginstitution studies, it is estimated that 4% to 9% of
children undergoing cardiac surgery will acquire this
complication.3-5
The mechanisms proposed for the development of
chylothorax after cardiac surgery include surgical trauma
to the thoracic duct or lymphatic tributaries, increased
central venous pressure after procedures such as partial
or complete cavopulmonary anastomoses, and the
development of central venous thrombosis with consequent
impairment of thoracic duct drainage.1 Accordingly, some
of the risk factors that have been found in single-
institution studies to be associated with the development
of chylothorax after cardiac surgery include type of
procedure,3,4 secondary chest closure,4 low weight,4
durations of cardiopulmonary bypass and crossclamping,4
and presence of trisomy 21.10 In particular, patients
undergoing a Fontan procedure or heart transplant seem
to be at the highest risk.3,11
Despite several small studies reporting the incidence of
postoperative chylothorax in pediatric cardiac surgical
patients, the actual risk factors for development of this
complication, the trends in treatment strategy use, and the
effect of this complication on outcomes have not been
adequately studied. The goal of this study was to use a
large multi-institution database to determine the incidence,ery c February 2014
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¼ International Classification of Diseases,
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DMATERIALS AND METHODS
Study Population
All patients younger than 18 years who underwent congenital heart
surgery or heart transplant from 2004 to 2011 in the Pediatric Health
Information System (PHIS) database were included in this retrospective
study.
The PHIS database is an administrative database that contains inpatient,
emergency department, ambulatory surgery, and observation data from 43
not-for-profit, tertiary care pediatric hospitals in the United States.
These hospitals are affiliated with the Children’s Hospital Association
(Overland Park, Kan). The data warehouse function for the PHIS database
is managed by Truven Health Analytics (Ann Arbor, Mich). For the
purposes of external benchmarking, participating hospitals provide
discharge and encounter data including demographic characteristics,
diagnoses, and procedures. Forty-two of these hospitals also submit
resource utilization data (eg, pharmaceutical, imaging, and laboratory
resources) into PHIS. Data are electronically collected directly from
existing elements located within each PHIS-participating hospital’s
electronic medical and financial record systems. The health information
management office of each PHIS-participating hospital is responsible for
data extraction and submission to PHIS. There is no manual data entry.
Data are stripped of identifiers at the time of data submission. Data are
subjected to a number of reliability and validity checks before being
included in the database. Data quality and reliability are ensured through
a joint effort between PHIS-participating hospitals and the Children’s
Hospital Association. Participating hospitals receive data quality reports
on submission to the data warehouse and are required to meet
predetermined quality thresholds before certification of data submission.
The Children’s Hospital Association used the PHIS Data Quality Program
to audit data at the time of submission, after submission, and after
production once in PHIS. For this study, data from 42 hospitals met study
criteria.
The PHIS database was queried to include all patients younger than
18 years who had either undergone a procedure with an assigned Risk
Adjustment for Congenital Heart Surgery-1 (RACHS) score or a heart
transplant (International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] procedure code 37.51) during an
inpatient admission within the study period.
Measurements
Patients who had an ICD-9-CM diagnosis code of 457.8 assigned to the
same admission as the RACHS procedure or the heart transplant were
considered to have acquired postoperative chylothorax. Even though theThe Journal of Thoracic and Cadate of the procedure is captured in the PHIS database, the date of diagnosis
of chylothorax is not.
Information on demographic data of sex, age, and race or ethnicity;
procedure complexity as assessed by RACHS score; year of surgery; use
of total parenteral nutrition (TPN), medium-chain triglycerides (MCT),
and octreotide; and total cost for the admission were extracted from the
database. Costs in the PHIS database are calculated from hospital charges
by means of multiple individual cost-to-charge ratios for each hospital.
All costs were adjusted to 2011 US dollars. Information on diagnosis of
Down syndrome (ICD-9-CM diagnosis code 758.0), Noonan syndrome
(ICD-9-CM diagnosis code 759.89), and Turner syndrome (ICD-9-CM
diagnosis code 758.6) was extracted. Similarly, a diagnosis of neck or
proximal upper extremity deep vein thrombosis (ICD-9-CM diagnosis
codes 453.83-453.87) was noted. The occurrence of a thoracic duct ligation
(ICD-9-CM procedure code 40.64) or a pleurodesis (ICD-9-CM procedure
codes 34.6 and 34.92) during the same admission but after the cardiac
surgical procedure date was included.
Age was classified in several groups according to age at admission:
neonates (30 days), infants (31 days and<1 year), young children
(1 year and<6 years), older children (6 years and<12 years) and
teenagers (12 years and<18 years). Race or ethnicity was classified as
white, Hispanic, black, and others.
The data were stratified according to procedure complexity by means of
RACHS score as provided by the PHIS database. The PHIS database
assigns a single RACHS score to each operation on the basis of a
predetermined algorithm. If a patient undergoes multiple procedures as
part of the same operation, the operation is assigned the RACHS score
for the highest-risk procedure. In our study, patients with RACHS scores
of 5 and 6 were included in the same group. Patients with several
separate operations during the same admission were assigned to a
separate group (multiple procedures). Similarly, patients undergoing
only a heart transplant during the admission were assigned to a separate
group.
To analyze the data according to hospital volume, the median annual
RACHS procedure volume was calculated for each hospital across the
years that the particular hospital contributed to the database. All hospitals
were then sorted from lowest to highest median volume. The median
volumes were cumulatively added, and the hospitals were divided into
quartiles according to these cumulative median volumes to ensure that
each of the four groups had a relatively equivalent number of patients.
The respective hospital volume quartile was then assigned to each entry
depending on the hospital where the patient had the procedure performed.
A similar analysis was performed to analyze the data according to median
surgeon volume.Data Analysis
The incidence of chylothorax was calculated for the entire group and for
each subgroup. To determine the effect of risk factors on the incidence of
chylothorax, univariate analyses were performed with c2 and Fisher exact
tests as appropriate. A logistic multivariate regressionmodel was created to
determine the influence of each of the risk factors after adjustment for
significant covariates. The results are presented as odds ratios (ORs) with
95% confidence intervals (CIs). The use of different treatment strategies
(TPN, MCT, octreotide, and surgical procedures) and changes with time
were analyzed with similar univariate methods.
The relationship between diagnosis of chylothorax and hospital stay and
cost was determined with the Student t test and logarithmic linear
regression models to adjust for covariates. The relationship between
chylothorax and in-hospital mortality was analyzed with c2 testing and
logistic regression for univariate and multivariate analyses, respectively.
All analyses were performed with the SAS 9.3 statistical software
package (SAS Institute Inc, Cary, NC). Data are expressed as numbers
and percentages or medians with interquartile ranges (IQRs) unless
otherwise specified.rdiovascular Surgery c Volume 147, Number 2 679
TABLE 1. Demographic characteristics of the overall cohort
Characteristics No. (%)
Age group
Neonates 18,419 (23.7)
Infants 27,514 (35.4)
Young children 19,187 (24.7)
Older children 6376 (8.2)
Teenagers 6281 (8.1)
Male 43,048 (55.4)
Race or ethnicity
White 40,925 (54.3)
Hispanic 14,316 (18.9)
Black 9747 (12.9)
Other 10,400 (13.8)
Genetic syndromes
Down syndrome 7343 (9.4)
Noonan syndrome 1820 (2.3)
Turner syndrome 394 (0.5)
Type of procedure
RACHS
1 9066 (11.7)
2 27,006 (34.7)
3 27,496 (35.4)
4 8354 (10.7)
5-6 2613 (3.4)
Heart transplant 1329 (1.7)
Multiple procedures 1913 (2.5)
Neck or upper vein thrombosis 175 (0.2)
Year
2004 7766 (10)
2005 8910 (11.4)
2006 9740 (12.5)
2007 10,378 (13.3)
2008 10,502 (13.5)
2009 10,255 (13.2)
2010 10,074 (12.9)
2011 10,152 (13.1)
RACHS, Risk Adjustment for Congenital Heart Surgery-1.
TABLE 2. Incidence of chylothorax associated with selected
procedures according to International Classification of Diseases,
Ninth Revision, Clinical Modification procedure codes
Procedures (ICD-9-CM procedure codes) Incidence (No. and%)
Atriopulmonary and cavopulmonary
anastomoses; Fontan (35.94, 39.21)
430/7589 (5.7)
Total correction of transposition of great
vessels (35.84)
125/2887 (4.3)
Heart transplant (37.51) 53/1329 (4.0)
Repair of congenital aortic arch anomalies*
(38.34, 38.35, 38.44, 38.45, 38.64, 38.65,
38.84, 38.85)
241/6515 (3.7)
Total repair of total anomalous pulmonary
venous connection (35.82)
71/1916 (3.7)
Total repair of tetralogy of Fallot (35.81) 182/5322 (3.4)
Repair of endocardial cushion defect
(35.54, 35.63, 35.73)
158/4682 (3.4)
Total repair of truncus arteriosus (35.83) 23/742 (3.1)
Systemic to pulmonary artery shunty (39.0) 64/3396 (1.9)
Repair of ventricular septal defect (35.53,
35.55, 35.62, 35.72)
150/9299 (1.6)
Patent ductus arteriosusz (38.34, 38.45,
38.64, 38.85)
14/1241 (1.1)
Repair of atrial septal defect (35.51, 35.52,
35.61, 35.71)
59/6660 (0.9)
ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical
Modification. *Includes patients with ICD-9-CM diagnosis codes 747.10 (coarctation
of aorta), 747.11(interrupted aortic arch), and 747.21 (congenital arch anomalies) as
the primary diagnosis. yIncludes only patients with a Risk Adjustment for Congenital
Heart Surgery-1 score of 3. zIncludes patients with ICD-9-CM diagnosis code
747.0 (patent ductus arteriosus) as the primary diagnosis.
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DRESULTS
A total of 77,777 patients in the PHIS database (43,048
[55%] male) with a median age of 6.7 months (IQR,
1.2 months–3.4 years) underwent cardiac surgery or cardiac
transplant. The details of the entire cohort can be found in
Table 1.
Incidence and Risk Factors for Development of
Chylothorax
The overall incidence of chylothorax within this cohort
was 2.8% (n ¼ 2205). Table 2 shows the incidence
of chylothorax for selected procedures according to
ICD-9-CM procedure codes. The procedures associated
with the highest incidence of chylothorax were those
related to high venous pressures, such as cavopulmonary
and atriopulmonary anastomoses (eg, Glenn and Fontan
procedures).680 The Journal of Thoracic and Cardiovascular SurgThe relationships between the different risk factors
and the incidence of chylothorax are shown in Table 3.
Chylothorax was more common in younger age groups,
with the incidence being the highest for neonates (4.2%,
n ¼ 771) and the lowest for teenagers (0.5%, n ¼ 32;
P < .0001). After adjustment for significant covariates,
neonates were approximately 7 times more likely to acquire
chylothorax than teenagers (OR, 7.0; 95% CI 4.6-11).
Patients with genetic syndromes were more likely to
acquire chylothorax. In particular, patients with Turner
syndrome were more than 4 times more likely to acquire
a chylothorax than those without, even after adjustment
for other covariates (OR, 4.5; 95% CI, 3.1-6.5). Patients
with a diagnosis of neck or upper extremity vein thrombosis
were almost 7 times more likely to acquire a chylothorax
(OR, 6.7; 95% CI, 4.6-9.7).
The development of chylothorax was also significantly
associated with procedure complexity, with the incidence
increasing from 1% for class 1 RACHS procedures to
5.2% for classes 5 and 6 (P<.0001). The incidence was
highest (9.6%) for patients undergoing multiple
procedures.
Hospitals in the highest quartile of annual volume had a
significantly lower incidence of chylothorax than the rest,ery c February 2014
TABLE 3. Risk factors associated with the development of
chylothorax
Variable
Incidence of
chylothorax
(No. and%)
Multivariate
analysis
(OR and 95% CI)
Sex
Male (n ¼ 43,048) 1274 (3) Reference
Female (n ¼ 34,729) 931 (2.7) 0.86 (0.78-0.94)
Race or ethnicity
White (n ¼ 40,925) 1188 (2.9) Reference
Hispanic (n ¼ 14,316) 468 (3.3) 1.16 (1.04-1.31)
Black (n ¼ 9747) 185 (1.9) 0.7 (0.59-0.83)
Other (n ¼ 12,789) 364 (2.9) 1.07 (0.93-1.22)
Age group
Neonates (n ¼ 18,419) 771 (4.2) 7.03 (4.61-10.7)
Infants (n ¼ 27,514) 886 (3.2) 7.44 (4.9-11.3)
Young children (n ¼ 19,187) 456 (2.4) 5.98 (3.93-9.12)
Older children (n ¼ 6376) 60 (0.9) 2.2 (1.35-3.61)
Teenagers (n ¼ 6281) 32 (0.5) Reference
Down syndrome
No (n ¼ 70,434) 1877 (2.7) Reference
Yes (n ¼ 7343) 328 (4.5) 1.66 (1.45-1.9)
Noonan syndrome
No (n ¼ 75,957) 2136 (2.8) Reference
Yes (n ¼ 1820) 69 (3.8) 1.42 (1.1-1.83)
Turner syndrome
No (n ¼ 77,383) 2169 (2.8) Reference
Yes (n ¼ 394) 36 (9.1) 4.47 (3.1-6.46)
Type of procedure
RACHS
1 (n ¼ 9066) 91 (1) Reference
2 (n ¼ 27,006) 560 (2.1) 1.78 (1.41-2.23)
3 (n ¼ 27,496) 808 (2.9) 2.61 (2.09-3.27)
4 (n ¼ 8354) 374 (4.5) 3.77 (2.96-4.81)
5-6 (n ¼ 2613) 136 (5.2) 4.27 (3.18-5.72)
Heart transplant (n ¼ 1329) 53 (4) 6.29 (2.45-16.14)
Multiple procedures (n ¼ 1913) 183 (9.6) 7.77 (5.92-10.21)
Neck or upper extremity vein thrombosis
No 2156 (2.8) Reference
Yes 49 (28.0) 6.68 (4.62-9.66)
Hospital annual volume
First quartile (n ¼ 19,849) 594 (3) Reference
Second quartile (n ¼ 20,542) 560 (2.7) 0.86 (0.75-0.98)
Third quartile (n ¼ 17,262) 706 (4.1) 1.26 (1.12-1.42)
Fourth quartile (n ¼ 20,124) 345 (1.7) 0.49 (0.42-0.58)
Surgeon annual volume (n ¼ 72,910)
First quartile (n ¼ 14,140) 393 (2.8) Reference
Second quartile (n ¼ 18,437) 482 (2.6) 0.95 (0.83-1.09)
Third quartile (n ¼ 19,373) 699 (3.6) 1.33 (1.16-1.52)
Fourth quartile (n ¼ 20,960) 499 (2.4) 0.93 (0.81-1.07)
Year
2004 (n ¼ 7766) 152 (2) Reference
2005 (n ¼ 8910) 185 (2.1) 1.1 (0.87-1.38)
2006 (n ¼ 9740) 243 (2.5) 1.3 (1.05-1.62)
2007 (n ¼ 10,378) 283 (2.7) 1.47 (1.19-1.81)
2008 (n ¼ 10,502) 327 (3.1) 1.66 (1.35-2.03)
2009 (n ¼ 10,255) 321 (3.1) 1.7 (1.38-2.09)
2010 (n ¼ 10,074) 316 (3.1) 1.59 (1.29-1.96)
2011 (n ¼ 10,152) 378 (3.7) 1.95 (1.59-2.39)
OR, Odds ratio; CI, confidence interval; RACHS, Risk Adjustment for Congenital
Heart Surgery-1.
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Deven after adjustment for procedure complexity and other
covariates (OR, 0.49; 95% CI, 0.42-0.58 vs first-quartile
hospitals). Figure 1 shows a plot with the incidence of
chylothorax for each hospital stratified by volume and
RACHS score. Even though hospitals with higher volume
tended to have a lower incidence of chylothorax, there
were some low-volume hospitals with similar incidence of
chylothorax to the high-volume centers. No significant
association was found between surgeon annual median
volume and the incidence of chylothorax.
The incidence of chylothorax has increased with time,
from 2% (n ¼ 152) in 2004 to 3.7% (n ¼ 378) in 2011
(P<.0001), even after adjustment for other covariates.
Treatment Strategies for Chylothorax
Among patients with chylothorax, TPN, MCT, and
octreotide were used in 1229 (56%), 38 (1.7%), and 360
(16%) patients, respectively. The median durations of
treatment with each medical strategy were 12 days
(IQR, 5-25 days), 4 days (IQR, 2-8 days), and 7 days
(IQR, 4-13 days), respectively. Surgical treatment (thoracic
duct ligation and pleurodesis) was used in 196 (8.9%)
patients a median of 18 days (IQR, 7-28 days) after the
cardiac procedure. Patients were discharged from the
hospital a median of 22 days (IQR, 10-47 days) after
surgical treatment of chylothorax. The use of
octreotide decreased with time, from 24% in 2004 to 13%
in 2011 (P ¼ .034). There was no significant change in the
use of the other treatment strategies with time (Figure E1).
Association Between the Development of
Chylothorax and Outcomes
The development of chylothorax was consistently
associated with a significantly longer hospital stay and
greater risk of in-hospital mortality throughout the different
subgroups (Table 4). After adjustment for significant
covariates (age, procedure complexity, neck or upper vein
thrombosis, and hospital volume), there was still a
significant association between the development of
chylothorax and the length of the hospital stay
(P<.0001) and the in-hospital mortality (OR, 2.13; 95%
CI,1.75-2.61). Similarly, chylothorax was associated with
a significantly increased cost of hospitalization, even after
adjustment for significant covariates (P<.0001).
The diagnosis of neck or upper vein thrombosis was
associated with significant increases in length of stay
(P < .0001), in-hospital mortality (OR, 4.08; 95%
CI, 2.64-6.31), and cost of hospitalization (P<.00001) after
adjustment for covariates. These associations were true for
patients with chylothorax and those without.
DISCUSSION
Chylothorax is an infrequent complication that carries
significant morbidity in patients undergoing pediatricrdiovascular Surgery c Volume 147, Number 2 681
FIGURE 1. Plots depicting the incidence of chylothorax and total volume for each hospital, stratified by type of procedure. Each individual bar represents a
different center, with different colors indicating different quartiles according to median hospital annual volume. The line represents the total cumulative
volume (VOL) for each hospital for that particular type of procedure. RACHS, Risk Adjustment for Congenital Heart Surgery-1.
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Dcardiac surgery. In this study, chylothorax was associated
with 2.8% of pediatric cardiac surgical procedures. The
incidence is slightly lower than contemporary reports
from multiple single-institution studies, which have shown
that chylothorax complicates 4% to 9% of pediatric cardiac
surgical operations.3-5682 The Journal of Thoracic and Cardiovascular SurgPrevious small single-institution studies have shown an
association between type of procedure and incidence of
chylothorax. It has been suggested that procedures that
lead to high systemic venous pressure may be more likely
to lead to postoperative chylothorax.1 In a study including
48 patients with postoperative chylothorax, Chan andery c February 2014
TABLE 4. Effects of chylothorax on outcomes
Hospital stay
(d, median and interquartile range) Mortality (No. and%)
Cost ($1000 US, median and
interquartile range)
No chylothorax Chylothorax No chylothorax Chylothorax No chylothorax Chylothorax
Age
Neonates 20 (13-36) 47 (30-74) 849/17,648 (4.8) 87/771 (11.3) 99 (63-165) 210 (132-332)
Infants 7 (5-13) 17 (9-36) 276/26,628 (1) 38/886 (4.3) 42 (30-69) 82 (48-160)
Young children 5 (3-9) 17 (10-30) 98/17,831 (0.5) 5/456 (1.1) 34 (24-53) 74 (47-127)
Older children 4 (3-6) 14 (6-27) 33/6316 (0.5) 1/60 (1.7) 35 (25-53) 59 (26-162)
Teenagers 5 (4-7) 10 (7-41) 28/6249 (0.45) 0/32 (0) 41 (30-62) 50 (32-198)
Type of procedure
RACHS
1 4 (3-5) 8 (5-26) 46/8975 (0.5) 7/91 (7.7) 25 (19-35) 36 (25-70)
2 6 (4-10) 17 (9-38) 168/26,446 (0.6) 22/560 (3.9) 39 (29-59) 78 (50-151)
3 9 (5-17) 23 (14-40) 436/26,688 (1.6) 21/808 (2.6) 53 (35-89) 106 (63-187)
4 13 (6-23) 23 (10-47) 233/7980 (2.9) 22/374 (5.9) 70 (36-121) 116 (42-213)
5-6 26 (17-41) 46 (35-62) 179/2477 (7.2) 19/136 (14) 134 (92-200) 223 (151-314)
Heart transplant 36 (17-72) 92 (52-138) 27/1276 (1.2) 4/53 (7.6) 279 (196-449) 450 (347-809)
Multiple procedures 40 (19-87) 66 (42-106) 195/1730 (11) 36/183 (19.7) 196 (101-392) 316 (202-582)
Neck or upper vein thrombosis
No 16 (4-16) 39 (12-49) 1264 (1.7) 120 (5.6) 82 (30-85) 186 (56-224)
Yes 70 (24-91) 80 (36-101) 20 (15.9) 11 (22.5) 366 (136-498) 447 (175-614)
Hospital volume
First quartile 7 (4-17) 23 (11-48) 386/19,255 (2) 41/594 (6.9) 47 (31-85) 98 (56-206)
Second quartile 7 (4-16) 28 (13-52) 394/19,982 (2) 33/560 (5.9) 46 (30-87) 126 (66-263)
Third quartile 7 (4-16) 27 (13-49) 231/16,556 (1.4) 37/706 (5.2) 48 (30-94) 129 (62-229)
Fourth quartile 7 (4-15) 23 (12-51) 273/19,779 (1.4) 20/345 (5.8) 42 (28-79) 93 (45-226)
RACHS, Risk Adjustment for Congenital Heart Surgery-1.
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nary anastomoses (Fontan and Glenn procedures) were
more likely to acquire postoperative chylothorax. In another
study, in which the incidence of postoperative chylothorax
was 9.2%, Biewer and associates4 found that complex
procedures such as Norwood procedures, repairs of
atrioventricular septal defects, procedures for transposition
of the great arteries, and truncus arteriosus repairs had an
incidence of chylothorax as high as 11% to 33%. These
studies were limited by the small numbers of procedures
in each category. By using a large multi-institution
database, our study showed that the incidence of
chylothorax does increase with higher procedure
complexity, as measured by RACHS score. Interestingly,
the incidence of chylothorax after heart transplant was
comparable to that after congenital cardiac procedures of
high complexity. By far the highest incidence of post-
operative chylothorax was that of patients who underwent
several cardiac procedures during the same admission.
Similarly, procedures associated with high systemic venous
pressure, such as Fontan procedures, carried a very high
incidence of chylothorax.
The incidence of chylothorax seems to have increased
during the last decade, with the risk of development of
chylothorax being 2 times greater in 2011 than in 2004,
even after adjustment for significant covariates. SimilarThe Journal of Thoracic and Caconclusions had been inferred from comparing older series
with an incidence of chylothorax of around 0.5% to 2%6-9
with newer series reporting an incidence as high as 4% to
9%.3-5 The increased incidence had been partly attributed
to increased complexity of pediatric cardiac surgical
procedures1,3; however, our study does not support that
assumption, because the findings remained significant
even after adjustment for procedure complexity according
to RACHS score. One possible explanation is that
RACHS score failed to completely control for procedure
complexity and that the higher incidence is indeed due to
more complex procedures being performed currently.
Another possible explanation for the increased incidence
is the recent trend toward earlier enteral feeding in these
patients. It is also possible that a heightened awareness of
this problem has led to an increase in the diagnosis of
chylothorax, rather than a real increase in its incidence.
Another factor that was found to be significantly
associated with development of chylothorax was age.
Neonates, infants, and younger children had a significantly
higher incidence of chylothorax than did older children and
teenagers. Although this finding had not been reported
previously, the median age in most single-institution series
has been younger than 1 year.3,4,12 Even though the obvious
differences in type of operations performed in the different
age groups may play a role in the incidence of chylothorax,rdiovascular Surgery c Volume 147, Number 2 683
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to a larger number of lymphatics and lymph nodes that
could be disrupted in this population. Chylothorax was
also more common among patients with Turner
syndrome, a finding likely related to the known lymphatic
abnormalities that are part of this syndrome.
An interesting and novel finding of the study was that the
incidence of chylothorax was lower in the highest volume
centers than in the lowest volume ones. As with other
diseases, increased volume as a surrogate for experience
can be associated with better management protocols and
lead to improved outcomes. It is unclear whether the
relationship between high-volume centers and lower
incidence of chylothorax is related to better preoperative
selection, differences in postoperative patient care and
feeding protocols, differences in the reporting of
chylothorax between centers, or differences in surgical
technique. In general, the incidence of chylothorax was
uniformly low among high-volume centers; however, there
were also some low- and medium-volume centers with
similarly low incidences of chylothorax. Thus there may
be certain practices, not identified as part of this study,
prevalent in high-volume centers and some lower volume
centers, that are responsible for the lower incidence of
chylothorax.
Interestingly, the incidence did not seem to be related to
annual surgeon volume. It is plausible that differences in
surgeon’s performance and surgical technique as they relate
to the development of chylothorax are more related to
whether a particular surgeon practices in a high-volume
center or not, or to other practices more prevalent among
high-volume hospitals, rather than to the actual number of
cases the surgeon performs within the center.
There is no overall consensus regarding the best manage-
ment of postoperative chylothorax. As such, institutions
have reported different algorithms that have been based
on physician experience and preference.3,4,13 The decision
among the various therapeutic strategies and the time
elapsed before moving to more invasive strategies is
variable and depends mainly on physician and
institutional preferences. Our analysis showed that the use
of TPN was common in these patients. Unfortunately,
because of the limitations of the PHIS database, it is
impossible to know whether TPN was used after the
diagnosis of chylothorax or during the regular recovery of
the patient before development of the complication. Even
though the PHIS database does not include information
on types of diet, MCT supplementation, which is
processed by pharmacy, was available. Use of MCT
supplementation in this study was extremely low, with
only 1.7% of patients receiving it. Whether this low
usage rate is real or due to underreporting in the database
is unclear. The use of octreotide decreased with time,
from 24% in 2004 down to 13% in 2011, probably684 The Journal of Thoracic and Cardiovascular Surgrelated to the recognition of some side effects and the
time that it takes for octreotide to be effective.13 Surgical
options for the treatment of chylothorax, such as
pleurodesis and thoracic duct ligation, are usually reserved
for patients with failure of conservative management, as
evidenced by the infrequent use and the timing of these
strategies in our study. Because of the limitations of the
database, the actual effectiveness of any of these strategies
on the resolution of chylothorax is not available.
The impact of development of chylothorax is
considerable, because it leads to increased morbidity.1
Our analysis showed that the diagnosis of chylothorax not
only significantly increased the hospital stay but was also
associated with a higher risk of mortality, even after
adjustment for age, procedure complexity, and hospital
volume. The adjusted mortality of patients with a diagnosis
of chylothorax was twice as high as that of patients who did
not carry such a diagnosis. These results should be taken
with caution, because the nature of this database did not
allow further adjustment of other comorbidities. The
increased morbidity and mortality from chylothorax
may be related to significant loss of protein, lipids,
lymphocytes, and electrolytes, which can lead to
nutritional, immunologic, hematologic, and metabolic
complications.1 Furthermore, patients with a diagnosis of
neck or proximal upper extremity deep vein thrombosis
had worse outcomes in this study. In addition to increased
morbidity and mortality, the diagnosis of chylothorax was
associated with a significant increase in hospital cost. To
the best of our knowledge, this is the first study to report
an increase in the incremental cost of treatment for patients
who acquire postoperative chylothorax.
This study has several limitations, mainly related to its
observational and retrospective nature and the fact that it
is based on a large national database primarily recording
hospital cost data. As such, long-term follow-up and robust
clinical information are not available, limiting the ability to
elaborate on the clinical risk factors and making it difficult
to perform an adequate risk adjustment. The diagnosis of
chylothorax is based on reporting from each institution by
ICD-9-CM diagnosis code rather than on a series of precise
diagnostic tests. It is known that the use of ICD-9-CM
diagnosis codes may underestimate the incidence of
diseases.14,15 It is therefore possible that the incidence of
chylothorax may be higher than the actual rate reported in
this study. Another limitation of this study is the lack of
information regarding the timing of diagnosis of
chylothorax with respect to the cardiac surgical
procedure. It was assumed that the chylothorax occurred
postoperatively, although it is possible though unlikely
that some patients may have had a diagnosis of
chylothorax before the surgical procedure.
The procedures in this study were determined from
procedure codes reported by the participating institutions.ery c February 2014
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therefore the definition of the procedures may not be as
reliable. To minimize variations in coding between
institutions, we therefore decided to use RACHS scores to
create the procedure groups. A limitation of this approach
is that cardiac surgical procedures without an assigned
RACHS score were not included in the study. It is
plausible that some of these procedures may have been
associated with a higher or lower incidence of chylothorax.
Information on reoperations, which intuitively would
seem to be potentially associated with a higher risk of
chylothorax, is not available in the PHIS database.
Despite these limitations, the use of a multi-institution
national database allows the compilation of multiple and
diverse cases to determine risk factors and treatment
strategies that would otherwise be impossible to analyze.
In conclusion, acknowledging the limitations of this
study, chylothorax is a significant problem in pediatric
cardiac surgery and is associated with increased mortality,
cost, and hospital stay. Further studies are warranted to
develop strategies for prevention and treatment of this
disease, especially among the group of patients at highest
risk, such as neonates undergoing complex congenital
cardiac procedures.References
1. Zuluaga MT. Chylothorax after surgery for congenital heart disease. Curr Opin
Pediatr. 2012;24:291-4.
2. McCulloch MA, Conaway MR, Haizlip JA, Buck ML, Bovbjerg VE, Hoke TR.
Postoperative chylothorax development is associated with increased incidence
and risk profile for central venous thromboses. Pediatr Cardiol. 2008;29:556-61.
3. Chan EH, Russell JL, Williams WG, Van Arsdell GS, Coles JG, McCrindle BW.
Postoperative chylothorax after cardiothoracic surgery in children. Ann Thorac
Surg. 2005;80:1864-70.
4. Biewer ES, Z€urn C, Arnold R, Gl€ockler M, Schulte-M€onting J, Schlensak C,
et al. Chylothorax after surgery on congenital heart disease in newborns and
infants—risk factors and efficacy ofMCT-diet. J Cardiothorac Surg. 2010;5:127.
5. Cormack BE, Wilson NJ, Finucane K, West TM. Use of Monogen for pediatric
postoperative chylothorax. Ann Thorac Surg. 2004;77:301-5.
6. Allen EM, van Heeckeren DW, Spector ML, Blumer JL. Management of
nutritional and infectious complications of postoperative chylothorax in
children. J Pediatr Surg. 1991;26:1169-74.
7. Higgins CB, Mulder DG. Chylothorax after surgery for congenital heart disease.
J Thorac Cardiovasc Surg. 1971;61:411-8.
8. Nguyen DM, Shum-Tim D, Dobell AR, Tchervenkov CI. The management of
chylothorax/chylopericardium following pediatric cardiac surgery: a 10-year
experience. J Card Surg. 1995;10:302-8.
9. Beghetti M, La Scala G, Belli D, Bugmann P, Kalangos A, Le Coultre C. Etiology
and management of pediatric chylothorax. J Pediatr. 2000;136:653-8.
10. Doell C, Bernet V, Molinari L, Beck I, Balmer C, Latal B. Children with genetic
disorders undergoing open-heart surgery: are they at increased risk for
postoperative complications? Pediatr Crit Care Med. 2011;12:539-44.
11. Chan SY, Lau W, Wong WH, Cheng LC, Chau AK, Cheung YF. Chylothorax in
children after congenital heart surgery. Ann Thorac Surg. 2006;82:1650-6.
12. Nath DS, Savla J, Khemani RG, Nussbaum DP, Greene CL, Wells WJ. Thoracic
duct ligation for persistent chylothorax after pediatric cardiothoracic surgery.
Ann Thorac Surg. 2009;88:246-51; discussion 251-2.
13. Panthongviriyakul C, Bines JE. Post-operative chylothorax in children: an
evidence-based management algorithm. J Paediatr Child Health. 2008;44:
716-21.
14. Johnson DW, Adair C, Brant R, Holmwood J, Mitchell I. Differences in
admission rates of children with bronchiolitis by pediatric and general emergency
departments. Pediatrics. 2002;110:e49.The Journal of Thoracic and Ca15. Hsu VP, Staat MA, Roberts N, Thieman C, Bernstein DI, Bresee J, et al. Use of
active surveillance to validate international classification of diseases code
estimates of rotavirus hospitalizations in children. Pediatrics. 2005;115:78-82.Discussion
Dr Glen Van Arsdell (Toronto, Ontario, Canada). I have no
disclosures that relate to this presentation.
In this report of nearly 80,000 patients undergoing congenital
heart surgery, Mery and colleagues have shown that not only is
chylothorax frustrating for caregivers, it can also be lethal.
Most of the findings are consistent with what we would expect.
Somewhat surprisingly, however, there was a lower incidence than
previously identified in single-institution case series, and therewas
a difference in incidence between institutions. Perhaps there is also
an increasing incidence with time. Of course, we would like to
know why these findings might be.
Dr Mery, bearing in mind the limitations of an administrative
database, and they are substantial, did you look for and were
you able to identify clues as to practice patterns that might help
explain a different incidence between institutions? The fact that
surgeon volume did not impact the incidence of chylothorax, but
institution volume did, suggests that institution protocols could
be conceivably more important than individual surgical technique.
For example, protocol findings might be differing age of treatment
between institutions for the same RACHS classification, or, for
example, a higher use of low–molecular weight heparin, which
might impact the thrombotic risk for chylothorax. Was there an
analysis that you performed in this regard that had either positive
or negative results?
Dr Mery. Thank you for your very insightful comments.
Indeed, some of the findings of this study were somewhat
surprising.
One of the problems with using administrative databases
that are based on ICD-9-CM codes is that you can actually
underestimate the incidence of disease. There are some studies
that have compared the incidences of reported diseases such as
bronchiolitis and aspergillosis in an administrative database with
actual clinical data and have found that the real incidence of
disease may be between 10% and 40% higher than that reported
in the administrative database. From this, I would say that the chy-
lothorax incidence is at least 2.8% and could actually be higher.
As far as the relationship between the incidence of chylothorax
and hospital volume goes, I totally agree with you. Some possible
explanations could be due to differences in protocols for enteral
feeding, patient selection, and postoperative patient management.
I submit that even surgical technique may play a role, even though
it may not be related to surgeon volume itself. Surgeons that
operate in hospitals that have higher volume may have different
techniques than surgeons that do not; obviously something we
cannot prove. Part of the explanation may also have to do with
the way the data were analyzed. If you actually look at the hospital
volume quartiles that we used, the highest hospital volume quartile
included only 5 hospitals, compared with 19 hospitals that
were included on the first quartile, so the data may be more
heterogeneous for the lower volume hospitals.
We did not look at the use of low–molecular weight heparin.
Dr Van Arsdell. I suspect there may be a few broad large
categories, such as drug usage or age, that you could see whetherrdiovascular Surgery c Volume 147, Number 2 685
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interesting analysis to perform.
In our own database, about 15% of patients did not fit into the
RACHS classification. These patients had a similar mortality to
RACHS 5 and 6. Were you able to account for all patients who
had heart surgery, even if they did not fit into a RACHS
classification? And if not, might that be some of the explanation
as to why there was a relatively low incidence of chylothorax?
DrMery. That is a very good point. By definition, we only took
patients who had a RACHS-associated procedure; that is how we
identified patients in the database who had cardiac surgery. We
could definitely be missing patients with a different incidence of
chylothorax. One of the limitations of the PHIS database is that
it uses ICD-9-CM diagnosis and procedure codes, and these can
be unreliable. For example, we do not know which patients had
Norwood procedures, because there is no ICD-9-CM procedure
code for a Norwood. It is instead a combination of procedure codes
for an atrial septectomy, an aortic arch reconstruction, and some
type of systemic-to-pulmonary shunt. That is why we relied on
the RACHS scores that are reported on this database, rather than
using particular procedure codes. We did not perform any analyses
comparing drug usage or age between institutions, but I agree that
it would be an interesting analysis.
Dr Van Arsdell. And my last question, you found this
increasing incidence of chylothorax with time. Similar to the first
question, did you look for practice pattern changes, such as billable
feedings, which you alluded to, that might suggest protocols that
would drive this change?
Before you answer that, congratulations on a great presentation
and a very nice manuscript as well. And thank you for stimulating
this discussion on an important topic.
Dr Mery. Thank you very much. We did not look at difference
in practice patterns. It may be true that the increase in incidence
that we are seeing might just be an increase in detection and
reporting, because there has been increased awareness of this
problem during the last few years. It is interesting, though, that
single-institution studies have also shown an increasing incidence
with time. The incidence in the 1970s and 1980s was reported to be
between 0.5% and 1%, and now it is much higher. It is unclear
whether that is a result of increased awareness, changes in enteral
feeding patterns, or actual increasing incidence.
Dr J. William Gaynor (Philadelphia, Pa). I have no
disclosures. I just want to mention a novel therapy that we have
been using recently that was developed by Dr Max Itkin, one of
our interventional radiologists, that has been very successful in
many cases. He uses percutaneous cannulation of the cisterna chyli
and then performs a lymphangiogram. He can identify anatomic
variations. He can sometimes identify a leaky vessel. And then
he embolizes with the thoracic duct or the lead. This has been
done in infants as young as 1 month, and it has been very, very
successful. We go to it much quicker than we used to sticking
with feeds and chest tube drainage and going in. We have all686 The Journal of Thoracic and Cardiovascular Surghad the frustration of trying to go in with somebody with a
chylothorax, and the lymph seems to be coming from everywhere
and you cannot identify a single leak. Obviously, this needs to be
replicated. He has published several papers on the technique, and it
has been very successful. Thank you, I enjoyed your presentation.
Dr Mery. I agree. Techniques like these may play a role in
trying to decrease the amount of time that goes from the diagnosis
of chylothorax to successful treatment. Our data do not allow us to
know when the diagnosis of chylothorax was made during the
admission, but the surgical procedures were performed a median
of 18 days after cardiac surgery. So there was good lapse of time
where conservative management was used, and these techniques
could potentially minimize that time.
Dr Peter Manning (St Louis, Mo). I think this is a good
example of a study where you have to be careful about drawing
conclusions about cause and effect versus association. You have
done a good job of that. As I think you said on your first slide,
the etiology of chylothorax can be multifactorial. Most of these
cases are not major thoracic duct injuries, but the thrombosis of
central veins or high central venous pressures are really important
factors, and consideration of these issues must be factored into the
evaluation and management of chylothorax.
My question is, do you think chylothorax itself is the morbid
entity, or is it a marker of very complex patients who have high
central venous pressures and have intravenous lines for a long
time that thrombose the superior vena cava?
Dr Mery. I think you are totally correct, and that is the difficult
part of database studies like this, because we cannot really assess
causation, just association. It is true, the development of
chylothorax may just be a proxy for multiple comorbidities that
are both increasing the risk of chylothorax in these patients and
at the same time increasing the risk of morbidity and mortality.
Dr Pedro J. Del Nido (Boston, Mass). Following up on that,
I think the institutional differences argue against an anatomic
factor. Presumably, these are the same children who are undergo-
ing surgery in one institution versus another. So I think one would
argue more for practice patterns as playing a significant role.
DrOsama Eltayeb (Tulsa, Okla). In your study, did you look at
the incidence of Chylothorax in early repair of tetralogy of Fallot?
Most of the centers have moved toward early repair; does that
increase the incidence of chylothorax? If not, maybe it is for the
panel to comment whether there is any increase of chylothorax
incidence after early repair of tetralogy.
DrMery.One of the problems with this database is that we rely
on very simplified codes, sowe cannot really obtain a lot of clinical
data. For example, trying to differentiate between Glenn and
Fontan procedures is impossible, because they are both coded as
cavopulmonary anastomoses unless the Fontan is a lateral
tunnel procedure, which would be coded as an atriopulmonary
anastomosis. So unfortunately, we do not have details in terms
of the particulars of procedures because of the nature of the
PHIS database.ery c February 2014
FIGURE E1. Use of treatment strategies for chylothorax across time.
TPN, Total parenteral nutrition; MCT, medium-chain triglycerides.
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